<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75903</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Outcomes of maximal androgen blockade in prostate cancer patients at a health area with Type 2 Reference Hospital (2nd part). Quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility</dc:title>
<dc:creator>Antoni Gelabert, Antoni</dc:creator>
<dc:language>es</dc:language>
<dc:source>Arch Esp Urol;62(7): 571-572, sept. 2009.</dc:source>
<dc:identifier>ibc-75903</dc:identifier>
<dc:title xml:lang="es">Resultados del uso en cáncer de próstata del bloqueo androgénico completo en área de salud del Hospital de Referencia Tipo 2 (2ª Parte). Calidad de Vida: Aplicación del instrumento EORTC QLQ-PR25 y resultados globales. Supervivencia ajustada a la calidad de vida, gasto farmacéutico y coste-utilidad</dc:title>
<dc:subject>^d29633</dc:subject>
<dc:subject>^d29625</dc:subject>
<dc:subject>^d740^s22015</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d11914^s22067</dc:subject>
<dc:subject>^d6885^s22000</dc:subject>
<dc:subject>^d11914^s22012</dc:subject>
<dc:subject>^d12225</dc:subject>
<dc:subject>^d13106</dc:subject>
<dc:subject>^d738^s22020</dc:subject>
<dc:subject>^d33368</dc:subject>
<dc:subject>^d16672</dc:subject>
<dc:type>article</dc:type>
<dc:date>200909</dc:date>
</metadata>
</record>
</ibecs-document>
